
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) - Research analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for Legend Biotech in a research report issued on Thursday, July 17th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of $0.14 per share for the quarter, up from their previous estimate of $0.08. HC Wainwright currently has a "Buy" rating and a $75.00 target price on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech's Q3 2026 earnings at $0.44 EPS and Q4 2026 earnings at $0.76 EPS.
Other research analysts also recently issued research reports about the company. Morgan Stanley restated an "overweight" rating and issued a $81.00 target price (up previously from $80.00) on shares of Legend Biotech in a research note on Thursday, July 10th. UBS Group set a $54.00 price target on Legend Biotech and gave the company a "buy" rating in a report on Wednesday, July 2nd. Truist Financial lowered their price target on Legend Biotech from $88.00 to $71.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Johnson Rice reissued a "buy" rating on shares of Legend Biotech in a report on Thursday. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $84.00 price objective on shares of Legend Biotech in a report on Tuesday, April 22nd. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $73.33.
Check Out Our Latest Stock Analysis on LEGN
Legend Biotech Stock Performance
NASDAQ:LEGN traded down $0.54 during trading on Friday, reaching $41.59. The company's stock had a trading volume of 1,461,490 shares, compared to its average volume of 1,371,946. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.07 and a current ratio of 5.20. The firm has a market cap of $7.64 billion, a price-to-earnings ratio of -70.49 and a beta of 0.19. Legend Biotech has a 12 month low of $27.34 and a 12 month high of $60.87. The firm has a 50 day moving average of $33.81 and a 200-day moving average of $34.44.
Legend Biotech (NASDAQ:LEGN - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.33. The company had revenue of $195.05 million for the quarter, compared to analysts' expectations of $190.83 million. Legend Biotech had a negative return on equity of 21.19% and a negative net margin of 29.95%. Legend Biotech's quarterly revenue was up 107.8% compared to the same quarter last year. During the same period last year, the business earned ($0.16) EPS.
Hedge Funds Weigh In On Legend Biotech
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Legend Biotech by 145.4% during the first quarter. GAMMA Investing LLC now owns 1,291 shares of the company's stock valued at $44,000 after purchasing an additional 765 shares during the period. Quarry LP purchased a new stake in Legend Biotech during the first quarter valued at approximately $48,000. Signaturefd LLC raised its position in Legend Biotech by 1,052.7% during the fourth quarter. Signaturefd LLC now owns 1,729 shares of the company's stock valued at $56,000 after purchasing an additional 1,579 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Legend Biotech during the fourth quarter valued at approximately $56,000. Finally, Brooklyn Investment Group raised its position in Legend Biotech by 1,114.8% during the first quarter. Brooklyn Investment Group now owns 1,725 shares of the company's stock valued at $59,000 after purchasing an additional 1,583 shares during the period. 70.89% of the stock is owned by institutional investors.
Legend Biotech Company Profile
(
Get Free Report)
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Read More

Before you consider Legend Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.
While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.